Global Rheumatology Therapeutics Market forecast and Analysis (2019-2026), by Disease Type, by Drug Type, by Distribution Channel, and by Region.

Global Rheumatology Therapeutics Market was valued at USD xx million in 2018 and is expected to reach at USD xx million by 2026 at a CAGR of xx% over forecast period 2019-2026. To know about the Research Methodology :- Request Free Sample Report Rheumatology is the discipline of internal medicine that involves the diagnosis and treatment of rheumatic diseases. Rheumatic diseases are characterized by the inflammation that affects joints, tendons, ligaments, bones and sometimes organs. Global Rheumatology Therapeutics Market is mainly driven by factors such as an Increasing prevalence of rheumatic disorders, increasing geriatric population in developed countries, increase in the number of new drugs approval and growing R&D investments. Also according to world arthritis day, more than 120 million people in the European Union are affected by some of the forms of arthritis. The growing geriatric population in developed countries is likely to be key driving factor for global rheumatology therapeutics market. However, introduction of biosimilars is major restraint for rheumatology therapeutics market. Increasing demand for biosimilar may hinder the conventional drug commonly used for rheumatology diseases treatment. Global Rheumatology Therapeutics Market is segmented by drug class, by disease indication, by route of administration, by distribution channel and by region. By drug type, the market is segmented into disease modifying anti-rheumatic drugs (DMARDs), non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, uric acid drugs and others. DMARDs drug type segment is expected to exhibit highest market share at a CAGR of xx% over forecast period thanks to an increase in usage of these drugs in early stage of disease and growing adoption of biologics drugs for treatment of moderate to severe rheumatoid arthritis and osteoarthritis. By geography, Global Rheumatology Therapeutics Market is segmented into APAC, North America, Europe, MEA& Africa and Latin America. North America dominated the market in 2018 and it is anticipated that North America will keep its dominance over forecast period thanks to increasing geriatric population in this region. Key players operating in this market are Abbvie, Inc., Bristol-Myers Squibb Company, Pfizer, Inc., Merck & Co., Inc., Amgen, Inc., Novartis AG, Janssen Biotech, Inc., Sanofi, Genentech, Inc., and Takeda Pharmaceutical. Among them, the companies such as AbbVie, Inc. These players are adopting various organic and inorganic growth strategies such as merger & acquisition, Joint ventures, expansion, strategic alliances, new product launches etc. to enhance their regional presence and business operation. The objective of the report is to present a comprehensive analysis of Global Rheumatology Therapeutics Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market are presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analysed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Global Rheumatology Therapeutics Market dynamics, structure by analysing the market segments and project the Global Rheumatology Therapeutics Market size. Clear representation of competitive analysis of key players By Type, Price, Financial position, Product Portfolio, Growth strategies, and Regional presence in the Global Rheumatology Therapeutics Market make the report investor’s guide. The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.

Global Rheumatology Therapeutics Market Scope: Inquire before buying

Global Rheumatology Therapeutics Market Segmentation by Disease Type

• Rheumatoid Arthritis • Ankylosing Spondylitis • Osteoarthritis • Lupus • Gout • Others

Global Rheumatology Therapeutics Market Segmentation by Drug Type

• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) • Analgesics • Disease Modifying Anti-Rheumatic Drugs (DMARDs) • Corticosteroids • Uric Acid • Others

Global Rheumatology Therapeutics Market Segmentation by Distribution Channel

• Retail Pharmacy • Online Pharmacy • Hospitals • Others

Global Rheumatology Therapeutics Market Segmentation by Region

• APAC • North America • Europe • MEA& Africa • Latin America

Global Rheumatology Therapeutics Major Market Players

• Abbvie, Inc. • Bristol-Myers Squibb Company, • Pfizer, Inc. • Merck & Co., Inc. • Amgen, Inc. • Novartis AG • Janssen Biotech, Inc. • Sanofi • Genentech, Inc. • Takeda Pharmaceutical • Johnson & Johnson Private Limited • F. Hoffmann-La Roche Ltd • UCB S.A. • Gilead Sciences, Inc. • Boehringer Ingelheim International GmbH • Regeneron Pharmaceuticals Inc.
Global Rheumatology Therapeutics Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.2. Secondary data 2.3.3. Secondary Sources 2.3.4. Primary Research 2.3.5. Data from Primary Sources 2.3.6. Breakdown of Primary Sources 3. Executive Summary: Global Rheumatology Therapeutics Market, by Market Value (US$ Mn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Rheumatology Therapeutics Market Analysis and Forecast 6.1. Global Rheumatology Therapeutics Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Rheumatology Therapeutics Market Analysis and Forecast, By Disease Type 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Rheumatology Therapeutics Market Value Share Analysis, By Disease Type 7.4. Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, By Disease Type 7.5. Global Rheumatology Therapeutics Market Analysis, By Disease Type 7.6. Global Rheumatology Therapeutics Market Attractiveness Analysis, By Disease Type 8. Global Rheumatology Therapeutics Market Analysis and Forecast, By Drug Type 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Rheumatology Therapeutics Market Value Share Analysis, By Drug Type 8.4. Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, By Drug Type 8.5. Global Rheumatology Therapeutics Market Analysis, By Drug Type 8.6. Global Rheumatology Therapeutics Market Attractiveness Analysis, By Drug Type 9. Global Rheumatology Therapeutics Market Analysis and Forecast, by Distribution Channel 9.1. Introduction and Definition 9.2. Key Findings 9.3. Global Rheumatology Therapeutics Market Value Share Analysis, by Distribution Channel 9.4. Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel 9.5. Global Rheumatology Therapeutics Market Analysis, by Distribution Channel 9.6. Global Rheumatology Therapeutics Market Attractiveness Analysis, by Distribution Channel 10. Global Rheumatology Therapeutics Market Analysis, by Region 10.1. Global Rheumatology Therapeutics Market Value Share Analysis, by Region 10.2. Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Region 10.3. Global Rheumatology Therapeutics Market Attractiveness Analysis, by Region 11. North America Rheumatology Therapeutics Market Analysis 11.1. Key Findings 11.2. North America Rheumatology Therapeutics Market Overview 11.3. North America Rheumatology Therapeutics Market Value Share Analysis, By Disease Type 11.4. North America Rheumatology Therapeutics Market Forecast, By Disease Type 11.4.1. Rheumatoid Arthritis 11.4.2. Ankylosing Spondylitis 11.4.3. Osteoarthritis 11.4.4. Lupus 11.4.5. Gout 11.4.6. Others 11.5. North America Rheumatology Therapeutics Market Value Share Analysis, By Drug Type 11.6. North America Rheumatology Therapeutics Market Forecast, By Drug Type 11.6.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 11.6.2. Analgesics 11.6.3. Disease Modifying Anti-Rheumatic Drugs (DMARDs) 11.6.4. Corticosteroids 11.6.5. Uric Acid 11.6.6. Others 11.7. North America Rheumatology Therapeutics Market Value Share Analysis, by Distribution Channel 11.8. North America Rheumatology Therapeutics Market Forecast, by Distribution Channel 11.8.1. Retail Pharmacy 11.8.2. Online Pharmacy 11.8.3. Hospitals 11.8.4. Others 11.9. North America Rheumatology Therapeutics Market Value Share Analysis, by Country 11.10. North America Rheumatology Therapeutics Market Forecast, by Country 11.10.1. U.S. 11.10.2. Canada 11.11. North America Rheumatology Therapeutics Market Analysis, by Country 11.12. U.S. Rheumatology Therapeutics Market Forecast, By Disease Type 11.12.1. Rheumatoid Arthritis 11.12.2. Ankylosing Spondylitis 11.12.3. Osteoarthritis 11.12.4. Lupus 11.12.5. Gout 11.12.6. Others 11.13. U.S. Rheumatology Therapeutics Market Forecast, By Drug Type 11.13.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 11.13.2. Analgesics 11.13.3. Disease Modifying Anti-Rheumatic Drugs (DMARDs) 11.13.4. Corticosteroids 11.13.5. Uric Acid 11.13.6. Others 11.14. U.S. Rheumatology Therapeutics Market Forecast, by Distribution Channel 11.14.1. Retail Pharmacy 11.14.2. Online Pharmacy 11.14.3. Hospitals 11.14.4. Others 11.15. Canada Rheumatology Therapeutics Market Forecast, By Disease Type 11.15.1. Rheumatoid Arthritis 11.15.2. Ankylosing Spondylitis 11.15.3. Osteoarthritis 11.15.4. Lupus 11.15.5. Gout 11.15.6. Others 11.16. Canada Rheumatology Therapeutics Market Forecast, By Drug Type 11.16.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 11.16.2. Analgesics 11.16.3. Disease Modifying Anti-Rheumatic Drugs (DMARDs) 11.16.4. Corticosteroids 11.16.5. Uric Acid 11.16.6. Others 11.17. Canada Rheumatology Therapeutics Market Forecast, by Distribution Channel 11.17.1. Retail Pharmacy 11.17.2. Online Pharmacy 11.17.3. Hospitals 11.17.4. Others 11.18. North America Rheumatology Therapeutics Market Attractiveness Analysis 11.18.1. By Disease Type 11.18.2. By Drug Type 11.18.3. By Distribution Channel 11.19. PEST Analysis 11.20. Key Trends 11.21. Key Development 12. Europe Rheumatology Therapeutics Market Analysis 12.1. Key Findings 12.2. Europe Rheumatology Therapeutics Market Overview 12.3. Europe Rheumatology Therapeutics Market Value Share Analysis, By Disease Type 12.4. Europe Rheumatology Therapeutics Market Forecast, By Disease Type 12.4.1. Rheumatoid Arthritis 12.4.2. Ankylosing Spondylitis 12.4.3. Osteoarthritis 12.4.4. Lupus 12.4.5. Gout 12.4.6. Others 12.5. Europe Rheumatology Therapeutics Market Value Share Analysis, By Drug Type 12.6. Europe Rheumatology Therapeutics Market Forecast, By Drug Type 12.6.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 12.6.2. Analgesics 12.6.3. Disease Modifying Anti-Rheumatic Drugs (DMARDs) 12.6.4. Corticosteroids 12.6.5. Uric Acid 12.6.6. Others 12.7. Europe Rheumatology Therapeutics Market Value Share Analysis, by Distribution Channel 12.8. Europe Rheumatology Therapeutics Market Forecast, by Distribution Channel 12.8.1. Retail Pharmacy 12.8.2. Online Pharmacy 12.8.3. Hospitals 12.8.4. Others 12.9. Europe Rheumatology Therapeutics Market Value Share Analysis, by Country 12.10. Europe Rheumatology Therapeutics Market Forecast, by Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Rest of Europe 12.11. Europe Rheumatology Therapeutics Market Analysis, by Country 12.12. Germany Rheumatology Therapeutics Market Forecast, By Disease Type 12.12.1. Rheumatoid Arthritis 12.12.2. Ankylosing Spondylitis 12.12.3. Osteoarthritis 12.12.4. Lupus 12.12.5. Gout 12.12.6. Others 12.13. Germany Rheumatology Therapeutics Market Forecast, By Drug Type 12.13.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 12.13.2. Analgesics 12.13.3. Disease Modifying Anti-Rheumatic Drugs (DMARDs) 12.13.4. Corticosteroids 12.13.5. Uric Acid 12.13.6. Others 12.14. Germany Rheumatology Therapeutics Market Forecast, by Distribution Channel 12.14.1. Retail Pharmacy 12.14.2. Online Pharmacy 12.14.3. Hospitals 12.14.4. Others 12.15. U.K. Rheumatology Therapeutics Market Forecast, By Disease Type 12.15.1. Rheumatoid Arthritis 12.15.2. Ankylosing Spondylitis 12.15.3. Osteoarthritis 12.15.4. Lupus 12.15.5. Gout 12.15.6. Others 12.16. U.K. Rheumatology Therapeutics Market Forecast, By Drug Type 12.16.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 12.16.2. Analgesics 12.16.3. Disease Modifying Anti-Rheumatic Drugs (DMARDs) 12.16.4. Corticosteroids 12.16.5. Uric Acid 12.16.6. Others 12.17. U.K. Rheumatology Therapeutics Market Forecast, by Distribution Channel 12.17.1. Retail Pharmacy 12.17.2. Online Pharmacy 12.17.3. Hospitals 12.17.4. Others 12.18. France Rheumatology Therapeutics Market Forecast, By Disease Type 12.18.1. Rheumatoid Arthritis 12.18.2. Ankylosing Spondylitis 12.18.3. Osteoarthritis 12.18.4. Lupus 12.18.5. Gout 12.18.6. Others 12.19. France Rheumatology Therapeutics Market Forecast, By Drug Type 12.19.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 12.19.2. Analgesics 12.19.3. Disease Modifying Anti-Rheumatic Drugs (DMARDs) 12.19.4. Corticosteroids 12.19.5. Uric Acid 12.19.6. Others 12.20. France Rheumatology Therapeutics Market Forecast, by Distribution Channel 12.20.1. Retail Pharmacy 12.20.2. Online Pharmacy 12.20.3. Hospitals 12.20.4. Others 12.21. Italy Rheumatology Therapeutics Market Forecast, By Disease Type 12.21.1. Rheumatoid Arthritis 12.21.2. Ankylosing Spondylitis 12.21.3. Osteoarthritis 12.21.4. Lupus 12.21.5. Gout 12.21.6. Others 12.22. Italy Rheumatology Therapeutics Market Forecast, By Drug Type 12.22.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 12.22.2. Analgesics 12.22.3. Disease Modifying Anti-Rheumatic Drugs (DMARDs) 12.22.4. Corticosteroids 12.22.5. Uric Acid 12.22.6. Others 12.23. Italy Rheumatology Therapeutics Market Forecast, by Distribution Channel 12.23.1. Retail Pharmacy 12.23.2. Online Pharmacy 12.23.3. Hospitals 12.23.4. Others 12.24. Spain Rheumatology Therapeutics Market Forecast, By Disease Type 12.24.1. Rheumatoid Arthritis 12.24.2. Ankylosing Spondylitis 12.24.3. Osteoarthritis 12.24.4. Lupus 12.24.5. Gout 12.24.6. Others 12.25. Spain Rheumatology Therapeutics Market Forecast, By Drug Type 12.25.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 12.25.2. Analgesics 12.25.3. Disease Modifying Anti-Rheumatic Drugs (DMARDs) 12.25.4. Corticosteroids 12.25.5. Uric Acid 12.25.6. Others 12.26. Spain Rheumatology Therapeutics Market Forecast, by Distribution Channel 12.26.1. Retail Pharmacy 12.26.2. Online Pharmacy 12.26.3. Hospitals 12.26.4. Others 12.27. Rest of Europe Rheumatology Therapeutics Market Forecast, By Disease Type 12.27.1. Rheumatoid Arthritis 12.27.2. Ankylosing Spondylitis 12.27.3. Osteoarthritis 12.27.4. Lupus 12.27.5. Gout 12.27.6. Others 12.28. Rest of Europe Rheumatology Therapeutics Market Forecast, By Drug Type 12.28.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 12.28.2. Analgesics 12.28.3. Disease Modifying Anti-Rheumatic Drugs (DMARDs) 12.28.4. Corticosteroids 12.28.5. Uric Acid 12.28.6. Others 12.29. Rest of Europe Rheumatology Therapeutics Market Forecast, by Distribution Channel 12.29.1. Retail Pharmacy 12.29.2. Online Pharmacy 12.29.3. Hospitals 12.29.4. Others 12.30. Europe Rheumatology Therapeutics Market Attractiveness Analysis 12.30.1. By Disease Type 12.30.2. By Drug Type 12.30.3. By Distribution Channel 12.31. PEST Analysis 12.32. Key Trends 12.33. Key Development 13. Asia Pacific Rheumatology Therapeutics Market Analysis 13.1. Key Findings 13.2. Asia Pacific Rheumatology Therapeutics Market Overview 13.3. Asia Pacific Rheumatology Therapeutics Market Value Share Analysis, By Disease Type 13.4. Asia Pacific Rheumatology Therapeutics Market Forecast, By Disease Type 13.4.1. Rheumatoid Arthritis 13.4.2. Ankylosing Spondylitis 13.4.3. Osteoarthritis 13.4.4. Lupus 13.4.5. Gout 13.4.6. Others 13.5. Asia Pacific Rheumatology Therapeutics Market Value Share Analysis, By Drug Type 13.6. Asia Pacific Rheumatology Therapeutics Market Forecast, By Drug Type 13.6.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 13.6.2. Analgesics 13.6.3. Disease Modifying Anti-Rheumatic Drugs (DMARDs) 13.6.4. Corticosteroids 13.6.5. Uric Acid 13.6.6. Others 13.7. Asia Pacific Rheumatology Therapeutics Market Value Share Analysis, by Distribution Channel 13.8. Asia Pacific Rheumatology Therapeutics Market Forecast, by Distribution Channel 13.8.1. Retail Pharmacy 13.8.2. Online Pharmacy 13.8.3. Hospitals 13.8.4. Others 13.9. Asia Pacific Rheumatology Therapeutics Market Value Share Analysis, by Country 13.10. Asia Pacific Rheumatology Therapeutics Market Forecast, by Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. ASEAN 13.10.5. Rest of Asia Pacific 13.11. Asia Pacific Rheumatology Therapeutics Market Analysis, by Country 13.12. China Rheumatology Therapeutics Market Forecast, By Disease Type 13.12.1. Rheumatoid Arthritis 13.12.2. Ankylosing Spondylitis 13.12.3. Osteoarthritis 13.12.4. Lupus 13.12.5. Gout 13.12.6. Others 13.13. China Rheumatology Therapeutics Market Forecast, By Drug Type 13.13.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 13.13.2. Analgesics 13.13.3. Disease Modifying Anti-Rheumatic Drugs (DMARDs) 13.13.4. Corticosteroids 13.13.5. Uric Acid 13.13.6. Others 13.14. China Rheumatology Therapeutics Market Forecast, by Distribution Channel 13.14.1. Retail Pharmacy 13.14.2. Online Pharmacy 13.14.3. Hospitals 13.14.4. Others 13.15. India Rheumatology Therapeutics Market Forecast, By Disease Type 13.15.1. Rheumatoid Arthritis 13.15.2. Ankylosing Spondylitis 13.15.3. Osteoarthritis 13.15.4. Lupus 13.15.5. Gout 13.15.6. Others 13.16. India Rheumatology Therapeutics Market Forecast, By Drug Type 13.16.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 13.16.2. Analgesics 13.16.3. Disease Modifying Anti-Rheumatic Drugs (DMARDs) 13.16.4. Corticosteroids 13.16.5. Uric Acid 13.16.6. Others 13.17. India Rheumatology Therapeutics Market Forecast, by Distribution Channel 13.17.1. Retail Pharmacy 13.17.2. Online Pharmacy 13.17.3. Hospitals 13.17.4. Others 13.18. Japan Rheumatology Therapeutics Market Forecast, By Disease Type 13.18.1. Rheumatoid Arthritis 13.18.2. Ankylosing Spondylitis 13.18.3. Osteoarthritis 13.18.4. Lupus 13.18.5. Gout 13.18.6. Others 13.19. Japan Rheumatology Therapeutics Market Forecast, By Drug Type 13.19.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 13.19.2. Analgesics 13.19.3. Disease Modifying Anti-Rheumatic Drugs (DMARDs) 13.19.4. Corticosteroids 13.19.5. Uric Acid 13.19.6. Others 13.20. Japan Rheumatology Therapeutics Market Forecast, by Distribution Channel 13.20.1. Retail Pharmacy 13.20.2. Online Pharmacy 13.20.3. Hospitals 13.20.4. Others 13.21. ASEAN Rheumatology Therapeutics Market Forecast, By Disease Type 13.21.1. Rheumatoid Arthritis 13.21.2. Ankylosing Spondylitis 13.21.3. Osteoarthritis 13.21.4. Lupus 13.21.5. Gout 13.21.6. Others 13.22. ASEAN Rheumatology Therapeutics Market Forecast, By Drug Type 13.22.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 13.22.2. Analgesics 13.22.3. Disease Modifying Anti-Rheumatic Drugs (DMARDs) 13.22.4. Corticosteroids 13.22.5. Uric Acid 13.22.6. Others 13.23. ASEAN Rheumatology Therapeutics Market Forecast, by Distribution Channel 13.23.1. Retail Pharmacy 13.23.2. Online Pharmacy 13.23.3. Hospitals 13.23.4. Others 13.24. Rest of Asia Pacific Rheumatology Therapeutics Market Forecast, By Disease Type 13.24.1. Rheumatoid Arthritis 13.24.2. Ankylosing Spondylitis 13.24.3. Osteoarthritis 13.24.4. Lupus 13.24.5. Gout 13.24.6. Others 13.25. Rest of Asia Pacific Rheumatology Therapeutics Market Forecast, By Drug Type 13.25.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 13.25.2. Analgesics 13.25.3. Disease Modifying Anti-Rheumatic Drugs (DMARDs) 13.25.4. Corticosteroids 13.25.5. Uric Acid 13.25.6. Others 13.26. Rest of Asia Pacific Rheumatology Therapeutics Market Forecast, by Distribution Channel 13.26.1. Retail Pharmacy 13.26.2. Online Pharmacy 13.26.3. Hospitals 13.26.4. Others 13.27. Asia Pacific Rheumatology Therapeutics Market Attractiveness Analysis 13.27.1. By Disease Type 13.27.2. By Drug Type 13.27.3. By Distribution Channel 13.28. PEST Analysis 13.29. Key Trends 13.30. Key Development 14. Middle East & Africa Rheumatology Therapeutics Market Analysis 14.1. Key Findings 14.2. Middle East & Africa Rheumatology Therapeutics Market Overview 14.3. Middle East & Africa Rheumatology Therapeutics Market Value Share Analysis, By Disease Type 14.4. Middle East & Africa Rheumatology Therapeutics Market Forecast, By Disease Type 14.4.1. Rheumatoid Arthritis 14.4.2. Ankylosing Spondylitis 14.4.3. Osteoarthritis 14.4.4. Lupus 14.4.5. Gout 14.4.6. Others 14.5. Middle East & Africa Rheumatology Therapeutics Market Value Share Analysis, By Drug Type 14.6. Middle East & Africa Rheumatology Therapeutics Market Forecast, By Drug Type 14.6.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 14.6.2. Analgesics 14.6.3. Disease Modifying Anti-Rheumatic Drugs (DMARDs) 14.6.4. Corticosteroids 14.6.5. Uric Acid 14.6.6. Others 14.7. Middle East & Africa Rheumatology Therapeutics Market Value Share Analysis, by Distribution Channel 14.8. Middle East & Africa Rheumatology Therapeutics Market Forecast, by Distribution Channel 14.8.1. Retail Pharmacy 14.8.2. Online Pharmacy 14.8.3. Hospitals 14.8.4. Others 14.9. Middle East & Africa Rheumatology Therapeutics Market Value Share Analysis, by Country 14.10. Middle East & Africa Rheumatology Therapeutics Market Forecast, by Country 14.10.1. GCC 14.10.2. South Africa 14.10.3. Rest of Middle East & Africa 14.11. Middle East & Africa Rheumatology Therapeutics Market Analysis, by Country 14.12. GCC Rheumatology Therapeutics Market Forecast, By Disease Type 14.12.1. Rheumatoid Arthritis 14.12.2. Ankylosing Spondylitis 14.12.3. Osteoarthritis 14.12.4. Lupus 14.12.5. Gout 14.12.6. Others 14.13. GCC Rheumatology Therapeutics Market Forecast, By Drug Type 14.13.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 14.13.2. Analgesics 14.13.3. Disease Modifying Anti-Rheumatic Drugs (DMARDs) 14.13.4. Corticosteroids 14.13.5. Uric Acid 14.13.6. Others 14.14. GCC Rheumatology Therapeutics Market Forecast, by Distribution Channel 14.14.1. Retail Pharmacy 14.14.2. Online Pharmacy 14.14.3. Hospitals 14.14.4. Others 14.15. South Africa Rheumatology Therapeutics Market Forecast, By Disease Type 14.15.1. Rheumatoid Arthritis 14.15.2. Ankylosing Spondylitis 14.15.3. Osteoarthritis 14.15.4. Lupus 14.15.5. Gout 14.15.6. Others 14.16. South Africa Rheumatology Therapeutics Market Forecast, By Drug Type 14.16.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 14.16.2. Analgesics 14.16.3. Disease Modifying Anti-Rheumatic Drugs (DMARDs) 14.16.4. Corticosteroids 14.16.5. Uric Acid 14.16.6. Others 14.17. South Africa Rheumatology Therapeutics Market Forecast, by Distribution Channel 14.17.1. Retail Pharmacy 14.17.2. Online Pharmacy 14.17.3. Hospitals 14.17.4. Others 14.18. Rest of Middle East & Africa Rheumatology Therapeutics Market Forecast, By Disease Type 14.18.1. Rheumatoid Arthritis 14.18.2. Ankylosing Spondylitis 14.18.3. Osteoarthritis 14.18.4. Lupus 14.18.5. Gout 14.18.6. Others 14.19. Rest of Middle East & Africa Rheumatology Therapeutics Market Forecast, By Drug Type 14.19.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 14.19.2. Analgesics 14.19.3. Disease Modifying Anti-Rheumatic Drugs (DMARDs) 14.19.4. Corticosteroids 14.19.5. Uric Acid 14.19.6. Others 14.20. Rest of Middle East & Africa Rheumatology Therapeutics Market Forecast, by Distribution Channel 14.20.1. Retail Pharmacy 14.20.2. Online Pharmacy 14.20.3. Hospitals 14.20.4. Others 14.21. Middle East & Africa Rheumatology Therapeutics Market Attractiveness Analysis 14.21.1. By Disease Type 14.21.2. By Drug Type 14.21.3. By Distribution Channel 14.22. PEST Analysis 14.23. Key Trends 14.24. Key Development 15. South America Rheumatology Therapeutics Market Analysis 15.1. Key Findings 15.2. South America Rheumatology Therapeutics Market Overview 15.3. South America Rheumatology Therapeutics Market Value Share Analysis, By Disease Type 15.4. South America Rheumatology Therapeutics Market Forecast, By Disease Type 15.4.1. Rheumatoid Arthritis 15.4.2. Ankylosing Spondylitis 15.4.3. Osteoarthritis 15.4.4. Lupus 15.4.5. Gout 15.4.6. Others 15.5. South America Rheumatology Therapeutics Market Value Share Analysis, By Drug Type 15.6. South America Rheumatology Therapeutics Market Forecast, By Drug Type 15.6.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 15.6.2. Analgesics 15.6.3. Disease Modifying Anti-Rheumatic Drugs (DMARDs) 15.6.4. Corticosteroids 15.6.5. Uric Acid 15.6.6. Others 15.7. South America Rheumatology Therapeutics Market Value Share Analysis, by Distribution Channel 15.8. South America Rheumatology Therapeutics Market Forecast, by Distribution Channel 15.8.1. Retail Pharmacy 15.8.2. Online Pharmacy 15.8.3. Hospitals 15.8.4. Others 15.9. South America Rheumatology Therapeutics Market Value Share Analysis, by Country 15.10. South America Rheumatology Therapeutics Market Forecast, by Country 15.10.1. Brazil 15.10.2. Mexico 15.10.3. Rest of South America 15.11. South America Rheumatology Therapeutics Market Analysis, by Country 15.12. Brazil Rheumatology Therapeutics Market Forecast, By Disease Type 15.12.1. Rheumatoid Arthritis 15.12.2. Ankylosing Spondylitis 15.12.3. Osteoarthritis 15.12.4. Lupus 15.12.5. Gout 15.12.6. Others 15.13. Brazil Rheumatology Therapeutics Market Forecast, By Drug Type 15.13.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 15.13.2. Analgesics 15.13.3. Disease Modifying Anti-Rheumatic Drugs (DMARDs) 15.13.4. Corticosteroids 15.13.5. Uric Acid 15.13.6. Others 15.14. Brazil Rheumatology Therapeutics Market Forecast, by Distribution Channel 15.14.1. Retail Pharmacy 15.14.2. Online Pharmacy 15.14.3. Hospitals 15.14.4. Others 15.15. Mexico Rheumatology Therapeutics Market Forecast, By Disease Type 15.15.1. Rheumatoid Arthritis 15.15.2. Ankylosing Spondylitis 15.15.3. Osteoarthritis 15.15.4. Lupus 15.15.5. Gout 15.15.6. Others 15.16. Mexico Rheumatology Therapeutics Market Forecast, By Drug Type 15.16.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 15.16.2. Analgesics 15.16.3. Disease Modifying Anti-Rheumatic Drugs (DMARDs) 15.16.4. Corticosteroids 15.16.5. Uric Acid 15.16.6. Others 15.17. Mexico Rheumatology Therapeutics Market Forecast, by Distribution Channel 15.17.1. Retail Pharmacy 15.17.2. Online Pharmacy 15.17.3. Hospitals 15.17.4. Others 15.18. Rest of South America Rheumatology Therapeutics Market Forecast, By Disease Type 15.18.1. Rheumatoid Arthritis 15.18.2. Ankylosing Spondylitis 15.18.3. Osteoarthritis 15.18.4. Lupus 15.18.5. Gout 15.18.6. Others 15.19. Rest of South America Rheumatology Therapeutics Market Forecast, By Drug Type 15.19.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 15.19.2. Analgesics 15.19.3. Disease Modifying Anti-Rheumatic Drugs (DMARDs) 15.19.4. Corticosteroids 15.19.5. Uric Acid 15.19.6. Others 15.20. Rest of South America Rheumatology Therapeutics Market Forecast, by Distribution Channel 15.20.1. Retail Pharmacy 15.20.2. Online Pharmacy 15.20.3. Hospitals 15.20.4. Others 15.21. South America Rheumatology Therapeutics Market Attractiveness Analysis 15.21.1. By Disease Type 15.21.2. By Drug Type 15.21.3. By Distribution Channel 15.22. PEST Analysis 15.23. Key Trends 15.24. Key Development 16. Company Profiles 16.1. Market Share Analysis, by Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 16.2.2. New Product Launches and Product Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A by Regions, Investment and Applications 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. Abbvie, Inc. 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Product Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Company Footprint 16.3.2. Bristol-Myers Squibb Company, 16.3.3. Pfizer, Inc. 16.3.4. Merck & Co., Inc. 16.3.5. Amgen, Inc. 16.3.6. Novartis AG 16.3.7. Janssen Biotech, Inc. 16.3.8. Sanofi 16.3.9. Genentech, Inc. 16.3.10. Takeda Pharmaceutical 16.3.11. Johnson & Johnson Private Limited 16.3.12. F. Hoffmann-La Roche Ltd 16.3.13. UCB S.A. 16.3.14. Gilead Sciences, Inc. 16.3.15. Boehringer Ingelheim International GmbH 16.3.16. Regeneron Pharmaceuticals Inc. 17. Primary Key Insights

About This Report

Report ID39217
Category Healthcare
Published DateDec 2019
Updated DateOct 2020
Contact Us